Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘Listing Regulations’), read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, Cohance Lifesciences has informed that Crisil ESG Ratings & Analytics (Crisil ESG Ratings) has voluntarily assigned an ESG Rating of ‘Crisil ESG 61 (Strong)’ and Core ESG Rating of ‘Crisil Core ESG 67 (Strong)’ to the Company. The link for the rating as published by Crisil ESG Ratings: https://www.crisilesg.com/en/home/esg-ratings.html. The Company has not engaged Crisil ESG Ratings for the ESG Rating. The rating has been independently determined by Crisil ESG Ratings based on publicly available information pertaining to the Company.
The above information is a part of company’s filings submitted to BSE.